AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (832.9 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Targeting TMEM16A/ANO1 inhibits the progression of BRAF mutant (V600E) melanoma through the MEK/ERK and AKT signaling pathways

Meiyun Shi1Jiahui Wang1Xingyu HuangLinsu LiuLutao LiuNa ZhouXinqi ShanHuaqun Chen( )
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, China

1 These authors contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

1

Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol. 2011;223(2):242–251.

2

Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888.

3

Wang H, Zou L, Ma K, et al. Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer. Mol Cancer. 2017;16(1):152.

4

Song Y, Gao J, Guan L, Chen X, Gao J, Wang K. Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-α signaling. Cell Death Dis. 2018;9:703.

5

Zuo Q, Liu J, Huang L, et al. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene. 2018;37(24):3275–3289.

Genes & Diseases
Article number: 101153
Cite this article:
Shi M, Wang J, Huang X, et al. Targeting TMEM16A/ANO1 inhibits the progression of BRAF mutant (V600E) melanoma through the MEK/ERK and AKT signaling pathways. Genes & Diseases, 2024, 11(6): 101153. https://doi.org/10.1016/j.gendis.2023.101153

67

Views

12

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics

Received: 28 May 2023
Published: 27 October 2023
© 2023 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Return